BamSEC and AlphaSense Join Forces
Learn More

Ngm Biopharmaceuticals Inc

Formerly NASDAQ: NGM
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.16
from 10-K 8 pages October 18, 2023 Jean-Frédéric Viret Dear Jean
12/34/56
EX-10.15
from 10-K 6 pages Material contract
12/34/56
EX-10.14
from 10-K 7 pages Material contract
12/34/56
EX-10.1
from 8-K 13 pages Limited Guaranty
12/34/56
EX-10.2
from 10-Q 6 pages Confidential
12/34/56
EX-10.1
from 10-Q 5 pages October 18, 2023 Jean-Frédéric Viret Dear Jean
12/34/56
EX-10.1
from 10-Q 4 pages Ngm Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy Approved by the Board of Directors: March 8, 2023
12/34/56
EX-10.14
from 10-K 4 pages Material contract
12/34/56
EX-10.9
from 10-K 4 pages Amended Non-Employee Director Compensation Policy Ngm Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy Approved by the Board of Directors: June 29, 2022
12/34/56
EX-10.1
from 10-Q 83 pages Britannia Oyster Point Lease
12/34/56
EX-10.1
from 10-Q 6 pages Confidential
12/34/56
EX-10.23
from 10-K 4 pages [*] = Certain Information Contained in This Document, Marked by Brackets, Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed Amendment No. 9 to the Multi-Product Licence Agreement Dated 31 October 2014 Between Lonza Sales AG and Ngm Biopharmaceuticals, Inc
12/34/56
EX-10.2
from 10-Q 5 pages Ngm Biopharmaceuticals, Inc. 2018 Equity Incentive Plan Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 180 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is of the Type That the Company Treats as Private or Confidential Amended and Restated Research Collaboration, Product Development and License Agreement by and Between Ngm Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp. Amended and Restated Research Collaboration, Product Development and License Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Material contract
12/34/56
EX-10.2
from 10-Q 2 pages Material contract
12/34/56
EX-10.18
from 10-K 5 pages Amendment No. 8 to the Multi-Product Licence Agreement Dated 31 October 2014 Between Lonza Sales AG and Ngm Biopharmaceuticals, Inc
12/34/56
EX-10.17
from 10-K 6 pages Amendment No. 7 to Multi-Product Licence Agreement Dated 31 October 2014 Between Lonza Sales AG and Ngm Biopharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.1
from 10-Q 2 pages May 20, 2020 Siobhan Nolan Mangini Dear Siobhan, on Behalf of Ngm Biopharmaceuticals, Inc. ("NGM" or the "Company"), We Are Pleased That You Will Be Joining the Company as Chief Financial Officer Reporting to Me. We Believe This Position Represents an Extraordinary Opportunity, and We Look Forward to Your Joining Our Exceptional Team
12/34/56